Combination therapy for cervical cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests combining two drugs (nituzumab and serplulimab) with focused radiation to treat cervical cancer that has not responded to other therapies. The goal is to see if this combination can shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have cervical cancer that is squamous cell type and has spread or come back despite standard treatments.
- You have at least one tumor that can be measured on a scan and a separate tumor that can be treated with a special type of focused radiation (SBRT).
- You are between 18 and 75 years old and feel well enough to be up and about (ECOG 0 or 1).
- You have not had chemotherapy or other cancer treatment in the last 4 weeks, and any side effects from prior treatments have mostly resolved.
- You are willing to provide a tumor sample (from a past biopsy or a new one) for testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug, serplulimab, for people with locally advanced cervical cancer. The goal is to see if it can help shrink or control the cancer before standard treatments.
This Phase 2 trial tests cadonilimab (an immunotherapy) combined with nab-paclitaxel (chemo) to treat cervical cancer that has come back or spread and did not respond to prior immune checkpoint medicines. It may help shrink tumors and improve disease control after prior immunotherapy failure.
This trial tests a new combination treatment for cervical cancer that has come back or spread. It may be an option for people who have not had previous systemic therapy for this stage of cancer.
This trial tests a combination of three types of cancer-fighting drugs—an immunotherapy (camrelizumab), a targeted therapy (famitinib), and chemotherapy—to treat cervical cancer that has returned or spread. The goal is to see if this combination works better than standard treatment.
This study tests whether adding the drug nimotuzumab to standard chemoradiotherapy (radiation plus chemo) and then continuing maintenance therapy works better for locally advanced cervical cancer (stages IB3 to IVA) than chemoradiotherapy alone.
This trial tests a combination of two drugs (nimotuzumab and tislelizumab) plus radiation for women whose cervical cancer has come back or spread to a few places in the body. The goal is to see if this treatment can shrink tumors and help patients live longer.
Hear when a new Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.